Sort
23,748 grants matching “melanoma”
Mechanisms of SK2/S1P Signaling in Regulating Tumor Immunotherapy
$195,098Shikhar Mehrotra · Medical University Of South Carolina · R21 · FY2015 · CA
CORE--Biostatistics Core D: U. of PA consortium
$195,064Phyllis A Gimotty · Wistar Institute · P01 · FY2007 · CA
Protein/Polymer Devices for Slow-Release of Immunotherapies to Treat Ovarian Cancer
$195,019Jonathan Kyle Pokorski · Case Western Reserve University · R21 · FY2017 · EB
The role of Absent in Melanoma 2 (Aim2) in CD8+ T cell regulation and Helicobacter-induced gastric pathology
$195,000John Y Kao · University Of Michigan At Ann Arbor · R21 · FY2021 · AI
Neurobiology of cytokine effects on CNS glutamate in IFN-alpha-induced depression
$195,000Jennifer C Felger · Emory University · R21 · FY2016 · MH
Enterovirus Vectors with Respiratory Tropism for Cancer Immunotherapy
$195,000Matthias Gromeier · Duke University · R21 · FY2009 · NS
Immunoengineering cellobiose as a fuel source for T cells
$195,000Manish J Butte · University Of California Los Angeles · R21 · FY2022 · AI
Mechanisms of autoimmune thyroid disease and the role of interferon-alpha
$194,969Jennifer Sophie Mammen · Johns Hopkins University · K23 · FY2018 · DK
Genetically Modified Natural Killer Cells for Cancer Immunotherapy
$194,940Branden S Moriarity · University Of Minnesota · R21 · FY2019 · CA
Gene Targeted Therapy of Brain Tumors
$194,754John H Sampson · Duke University · R21 · FY2010 · NS
Isolation and Characterization of Prostrate Antigen Specific High Affinity TCR
$194,700Shikhar Mehrotra · Medical University Of South Carolina · R21 · FY2010 · CA
Immune Mechanisms in Choroidal Neovascularization
$194,641Rajendra S Apte · Washington University · K08 · FY2007 · EY
Phase I trial of PHP with high-dose IL-2
$194,637Wolfram E Samlowski · University Of Utah · R21 · FY2006 · CA
Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
$194,590Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2022 · CA
Targeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
$194,590Brian C Miller · Harvard Medical School · K08 · FY2020 · CA
Targeting Unique Meyloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations
$194,589Brian C Miller · Univ Of North Carolina Chapel Hill · K08 · FY2021 · CA
Aptamer-Based Nanotechnology for Detection of Plasma Melanoma Markers
$194,565Gary A Clawson · Pennsylvania State Univ Hershey Med Ctr · R21 · FY2009 · CA
Tumor-directed immunostimulatory nanoparticles for novel 'prime-pull'cancer vaccination
$194,524Prabhani Atukorale · University Of Massachusetts Amherst · K22 · FY2021 · CA
Multiple Antigen-Engineered DC Immunization and IFNalpha-2b Boost for Metastatic Melanoma
$194,503Lisa Helene Butterfield · University Of Pittsburgh At Pittsburgh · P50 · FY2014 · CA
Developing inducible CRISPR to identify molecular targets in melanoma
$194,445Matthew Wayne Vanbrocklin · University Of Utah · R21 · FY2015 · CA
Core A: Administrative Core
$194,411Marcus W Bosenberg · Yale University · P50 · FY2024 · CA
Core Clinical Centers for the Blood and Marrow Transplant Clinical Trials Network (UG1)
$194,404Joseph A Pidala · H. Lee Moffitt Cancer Ctr & Res Inst · UG1 · FY2017 · HL
PEPTIDE TARGETING OF IL12 TO MALIGNANT ENDOTHELIUM
$194,400University Of Wisconsin Madison · R01 · FY2000 · CA
Glycosylation as a Regulator of Tropism of Melanoma Metastasis - Resubmission - 1
$194,400Praveen Agrawal · Albert Einstein College Of Medicine · K22 · FY2023 · CA
Glycosylation as a Regulator of Tropism of Melanoma Metastasis - Resubmission - 1
$194,400Praveen Agrawal · Albert Einstein College Of Medicine · K22 · FY2021 · CA